This article was originally published in The Tan Sheet
Aleve pain reliever sales advanced 27.5% to $302.3 mil. (E1=$1.33) in 2006 (ended Dec. 31), Bayer announces March 15. One-A-Day achieved sales growth of 5.1% to $165.1 mil. and Alka-Seltzer revenues increased 6.3% to $101 mil. for the year, firm adds. The brands helped drive sales of Bayer's Consumer Health Consumer Care Division, which jumped 7.5% to $3.37 bil. for the year, the company reports, noting it doubled sales of its OTC pharmaceuticals franchise during the year. The Consumer Health segment had net sales of $5.66 bil., representing growth of 8.1%. The company is continuing expansion of the Consumer Health division abroad, particularly in China, with the recent purchase of OTC company Topsun's cough/cold portfolio (1"The Tan Sheet" Oct. 30, 2006, p. 9). The HealthCare group's net sales grew 46.6% to $15.62 bil., and earnings before interest, taxes, depreciation and amortization before special items soared 75.7% to $3.48 bil. Bayer is targeting underlying EBITDA margin growth of about 27% in HealthCare in 2009...
You may also be interested in...
Bayer expects its purchase of Topsun Science & Technology's nonprescription cough and cold portfolio to "substantially increase Bayer Consumer Care's presence in China, one of the fastest growing OTC markets in the world," the firm states Oct. 25
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: